LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

Home・Lista de Ações・AstraZeneca PLC

AstraZeneca PLC

Fechado

SetorSaúde

187.25 -1.32

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

186.25

Máximo

189.72

Indicadores-chave
By Trading Economics
Rendimento	1.6B 3.9B
Vendas	-215M 15B
P/E Médio do Setor	27.887 49.701
EPS	1.29
Rendimento de Dividendos	1.74
Margem de lucro	25.602
Funcionários	96,100
EBITDA	1.1B 5.7B

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+13.75% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	1.74% 2.39%
Próximos Ganhos	27 de jul. de 2026
Próxima data de ex-dividendo	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-3.5B 287B
Abertura anterior	188.57
Fecho anterior	187.25

Sentimento de Notícias

By Acuity

48%

52%

149 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

N/A / 69.55 Suporte e Resistência

AstraZeneca PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2026, 16:28 UTC

Ganhos

Correction to AstraZeneca Update

29 de abr. de 2026, 15:11 UTC

Ganhos

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

29 de abr. de 2026, 06:31 UTC

Ganhos

AstraZeneca Gets Revenue Boost From Cancer Drugs

21 de mai. de 2026, 11:06 UTC

Conversa de Mercado

AstraZeneca Set for Busy End of Year -- Market Talk

13 de mai. de 2026, 12:29 UTC

Conversa de Mercado

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

13 de mai. de 2026, 11:54 UTC

Conversa de Mercado

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

1 de mai. de 2026, 09:31 UTC

Conversa de Mercado

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

29 de abr. de 2026, 10:29 UTC

Conversa de Mercado

Ganhos

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

29 de abr. de 2026, 10:06 UTC

Conversa de Mercado

Ganhos

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 de abr. de 2026, 09:53 UTC

Conversa de Mercado

Ganhos

AstraZeneca Seems in Fine Health -- Market Talk

29 de abr. de 2026, 06:05 UTC

Ganhos

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

29 de abr. de 2026, 06:04 UTC

Ganhos

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

29 de abr. de 2026, 06:04 UTC

Ganhos

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

29 de abr. de 2026, 06:03 UTC

Ganhos

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

29 de abr. de 2026, 06:03 UTC

Ganhos

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

29 de abr. de 2026, 06:02 UTC

Ganhos

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

29 de abr. de 2026, 06:01 UTC

Ganhos

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

29 de abr. de 2026, 06:01 UTC

Ganhos

AstraZeneca Backs 2026 View

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Adj EPS $2.58

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Rev $15.29B

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Pretax Pft $3.91B

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Oper Pft $4.25B

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Net Pft $3.08B

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q EPS $1.97

27 de abr. de 2026, 10:48 UTC

Conversa de Mercado

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

10 de abr. de 2026, 11:57 UTC

Conversa de Mercado

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

10 de abr. de 2026, 10:26 UTC

Conversa de Mercado

Ganhos

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2 de abr. de 2026, 09:16 UTC

Conversa de Mercado

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

27 de mar. de 2026, 10:40 UTC

Conversa de Mercado

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

27 de mar. de 2026, 10:17 UTC

Conversa de Mercado

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

Comparação entre Pares

Variação de preço

AstraZeneca PLC Previsão

Preço-alvo

By TipRanks

13.75% parte superior

Previsão para 12 meses

Média 215.841 USD 13.75%

Máximo 249.715 USD

Mínimo 151.708 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para AstraZeneca PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

Comprar

Manter

Vender

Com base em 15 analistas que deram avaliações de ações para AstraZeneca PLC - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

N/A / 69.55Suporte e Resistência

Recent bearish events outweigh bullish events.

Sentimento

By Acuity

149 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.